SAFE AND EFFECTIVE COMBINATION OF ULTRALONG-ACTING BASAL INSULIN DEGLUDEC AND ULTRA-SHORT ACTING INSULINE ASPART IN CHILDREN AND ADOLESCENTS WITH TYPE 1 DIABETES MELLITUS
- Authors: Girsh Y.V1, Veliyeva O.A1
-
Affiliations:
- BI HE of Khanty-Mansiysk Autonomous District-Yugra “Surgut State University"
- Issue: No 5 (2017)
- Pages: 8-13
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/289800
- ID: 289800
Cite item
Open Access
Access granted
Abstract
Achievement of satisfactory glycemic control in children and adolescents with type 1 diabetes mellitus keeps on to be one of the most difficult task of modern diabetology. The usage of a new generation basal insulin, insulin degludec with ultra-long action and the lowest variability of hypoglycemic activity, opens the new opportunities for achieving high quality of treatment in pediatric patients. It allows a significant improvement of the main parameters of glycemic control with a low risk of hypoglycemia, and has a good profile of tolerability and safety, as well as a convenient treatment regimen. The article presents the results of treatment of 27 type 1 diabetic patients aged 5-17 years using insulin degludec, including the dynamic of the main parameters of glycemic control depending on the age and the particulars of switching to the new insulin product and its titration.
Full Text
About the authors
Ya. V Girsh
BI HE of Khanty-Mansiysk Autonomous District-Yugra “Surgut State University"
Email: yanaef@yandex.ru
MD, Prof. at the Department of Children’s Diseases Surgut
O. A Veliyeva
BI HE of Khanty-Mansiysk Autonomous District-Yugra “Surgut State University"Medical Institute Surgut
References
- The Diabetes Control and Complications Trial / Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA. 2002;287:2563-69.
- Clarke W., Jones T., Rewers A., Dunger D., Klingensmith G.J. Assessment and management of hypoglycemia in children and adolescents with diabetes. Pediatr. Diabetes. 2009;10(Suppl.12):134-45.
- Гильбурд О.А., Гирш Я.В., Миронова Н.А. Репертуар невербального поведения при аффективных расстройствах у детей и подростков с сахарным диабетом 1 типа. Сибирский вестник психиатрии и наркологии. 2012;4(73):53-8.
- Гирш Я.В., Гильбурд О.А., Миронова Н.А. Влияние территориальных особенностей на формирование аффективных расстройств у детей и подростков с сахарным диабетом. Сахарный диабет. 2010:4:107-8.
- Heise T., Hermanski L., Nosek L., Feldman A., Rasmussen S., Haahr H. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes, Obes. Metab. 2012;14(9):859-64.
- Heller S., Buse J., Fisher M. et al. Insulin degludec, an ultra-long acting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379:1489-97.
- Thalangea N., Deebb L., lotova V., Kawamura T., Klingensmithe G., Philotheou A., Silverstein J., Tumini S., Ocampo Francisco A.M., Kinduryte O., Danne T. Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes. Pediatr. Diabetes. 2015;16(3):164-76.
- Rewers M., Pihoker C., Donoghue Hanas R., Swift P., Klingensmith G.J. ISPAD Clinical Practice Consensus Guidelines 2014 Compendium. Assessment and monitoring of glycemic control in children and adolescents with diabetes. Pediatr. Diabetes. 2014;15(Suppl.20):102-14.
- Дедов И.И., Шестакова М.В. Алгоритмы специализированной медицинской помощи больным сахарным диабетом, 7-й выпуск. М., 2015. 112 с.
Supplementary files
